GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » Shiller PE Ratio

Imunon (Imunon) Shiller PE Ratio : (As of May. 27, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Imunon Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Imunon Shiller PE Ratio Historical Data

The historical data trend for Imunon's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Shiller PE Ratio Chart

Imunon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Imunon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Imunon's Shiller PE Ratio

For the Biotechnology subindustry, Imunon's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Imunon's Shiller PE Ratio falls into.



Imunon Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Imunon's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Imunon's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.52/131.7762*131.7762
=-0.520

Current CPI (Mar. 2024) = 131.7762.

Imunon Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -79.799 100.560 -104.571
201409 -83.999 100.428 -110.219
201412 -54.599 99.070 -72.624
201503 -73.499 99.621 -97.223
201506 -56.699 100.684 -74.208
201509 -39.900 100.392 -52.374
201512 -50.399 99.792 -66.552
201603 -50.399 100.470 -66.103
201606 -39.450 101.688 -51.123
201609 -48.300 101.861 -62.485
201612 -39.300 101.863 -50.841
201703 -46.350 102.862 -59.379
201706 -11.850 103.349 -15.109
201709 -10.500 104.136 -13.287
201712 -4.064 104.011 -5.149
201803 -3.750 105.290 -4.693
201806 -6.900 106.317 -8.552
201809 -3.900 106.507 -4.825
201812 4.800 105.998 5.967
201903 -1.800 107.251 -2.212
201906 -4.350 108.070 -5.304
201909 -3.750 108.329 -4.562
201912 -1.500 108.420 -1.823
202003 -3.000 108.902 -3.630
202006 -2.700 108.767 -3.271
202009 -3.600 109.815 -4.320
202012 -0.785 109.897 -0.941
202103 -3.310 111.754 -3.903
202106 -0.950 114.631 -1.092
202109 -0.940 115.734 -1.070
202112 -0.710 117.630 -0.795
202203 -1.820 121.301 -1.977
202206 -0.870 125.017 -0.917
202209 -0.870 125.227 -0.916
202212 -1.610 125.222 -1.694
202303 -0.680 127.348 -0.704
202306 -0.610 128.729 -0.624
202309 -0.370 129.860 -0.375
202312 -0.520 129.419 -0.529
202403 -0.520 131.776 -0.520

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Imunon  (NAS:IMNN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Imunon Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Imunon's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon (Imunon) Business Description

Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Executives
James E Dentzer director C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne director, officer: President and CEO 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Michael H Tardugno officer: Chief Executive Offier 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Frederick J. Fritz director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John officer: Chief Accounting Officer C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Stacy Lindborg director C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Donald P Braun director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church officer: Chief Financial Officer
Robert W Hooper director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc. 10 percent owner 601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer officer: Chief Scientific Officer C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver director 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107